Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. filed an amended Schedule 13G on November 16, 2026, disclosing beneficial ownership of 1,740,230 American Depositary Shares of AgomAb Therapeutics NV as of September 30, 2026.

Key Highlights

  • Three reporting persons: Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report beneficial ownership of 1,740,230 shares.
  • Ownership stake: Each reporting person holds 3.5% of AgomAb Therapeutics NV common shares, based on 49,247,975 common shares outstanding as of March 31, 2026.
  • Direct holder: The 1,740,230 ADSs are directly held by Redmile Biopharma Investments III, L.P., a private investment vehicle for which Redmile Group, LLC serves as investment manager.
  • No sole voting or dispositive power: All three reporting persons report 0 shares with sole voting power and 0 shares with sole dispositive power; all 1,740,230 shares carry shared voting and shared dispositive power.
  • Beneficial ownership disclaimed: According to the filing, Redmile and Mr. Green each disclaim beneficial ownership of these securities, "except to the extent of its or his pecuniary interest in such securities, if any."
  • Event date: The date of event requiring this filing is September 30, 2026.

Redmile Group's Amended Beneficial Ownership Position in AgomAb Therapeutics

According to the filing, Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. (RBI III) jointly filed Amendment No. 1 to Schedule 13G with the SEC on November 16, 2026. The event triggering the amendment occurred on September 30, 2026. The filing covers common shares of AgomAb Therapeutics NV, a Belgian issuer whose principal executive offices are located at Posthoflei 1/6, 2600 Antwerpen, Belgium.

The filing discloses that as of September 30, 2026, each reporting person's beneficial ownership consists of 1,740,230 ADSs, with each ADS representing one common share. The ADSs are directly held by RBI III. The filing states that Redmile Group, LLC "may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all Common Shares underlying the ADSs held by RBI III," and that Jeremy C. Green "may be deemed to beneficially own these securities as the principal of Redmile." Redmile Group, LLC is organized in Delaware, while Mr. Green is a citizen of the United Kingdom, and RBI III is organized in Delaware.

The 3.5% ownership percentage is calculated against 49,247,975 common shares outstanding as of March 31, 2026, as reported by AgomAb Therapeutics NV in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on April 23, 2026. The filing also notes that CUSIP number 00860C102 has been assigned to the issuer's ADSs, and that "there is no CUSIP number assigned to the Common Shares." The filing qualifies under Item 5 as ownership of 5 percent or less of a class.

What Was Disclosed

Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. filed an amended Schedule 13G disclosing a combined beneficial ownership of 1,740,230 ADSs, equal to 3.5% of AgomAb Therapeutics NV common shares, as of September 30, 2026.